Blood Sci. 2023 Jan 4;5(2):136-137. doi: 10.1097/BS9.0000000000000148. eCollection 2023 Apr.
NO ABSTRACT
PMID:37228772 | PMC:PMC10205213 | DOI:10.1097/BS9.0000000000000148
Recent Content
- A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast
- Talquetamab and Teclistamab Achieve Deep, Durable Responses in Patients With Relapsed, Refractory Multiple Myeloma
- Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
- Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma
- Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
- Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
- IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
- Combination induces durable responses in advanced multiple myeloma
- Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
- Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma